Loading...
Market
What will be the FDA's decision on AMT-130 by end of 2025?
2
Resolution / Starting Odds
Full Approval • 25%
Accelerated Approval • 25%
Conditional Approval • 25%
Rejection • 25%
FDA approval announcements and uniQure press releases
Story
uniQure Aligns with FDA for BLA Submission and Accelerated Approval of AMT-130 in Phase I/II Huntington's Disease Studies
Dec 10, 2024, 12:18 PM
uniQure has announced that the FDA has agreed that data from its ongoing Phase I/II studies for AMT-130, a treatment for Huntington's Disease, may serve as the primary basis for a Biologics License Application (BLA) submission under the Accelerated Approval pathway. This alignment with the FDA is seen as a significant step forward for the company, as it establishes the use of natural history external control data in the review process. The FDA's flexibility in review standards for gene therapy applications is also noted, with emphasis on the importance of biomarkers like mHTT and NfL being deprioritized in this context. The announcement has generated positive sentiment among investors, drawing comparisons to previous successful approvals in the biotech sector.
View original story
Similar markets
BLA submission • 25%
Phase III trial initiation • 25%
Conditional approval • 25%
No progress • 25%
Yes • 50%
No • 50%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worse outcomes • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 50% efficacy • 25%
50-69% efficacy • 25%
70-89% efficacy • 25%
90% or higher efficacy • 25%
Highly positive • 25%
Moderately positive • 25%
Neutral • 25%
Negative • 25%
FDA • 33%
EMA • 33%
Both • 34%
Phase III trial initiation • 25%
FDA accelerated approval • 25%
New interim data release • 25%
Other milestone • 25%